MedTrace Logo

Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study

NCT07729917 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-07-28

No results posted yet for this study

Summary

This study is a prospective, multicenter, open-label, umbrella phase II clinical trial. Based on different multigene expression profiling subtypes and potential molecular characteristics of various pathways, 8 treatment arms and 13 treatment groups are preliminarily designed. After successful screening, investigators will assign eligible subjects to a treatment group based on the patient's genetic test report (if available) and performance status. For subjects without a genetic test report, they will be allocated to Arm H to receive immunotherapy combined with chemotherapy or other regimens.

Conditions

Interventions

DRUG

BRCA 1/2 mutation inhibitor

BRCA 1/2 mutation inhibitor

DRUG

HER2 target therapy

HER2 target therapy

DRUG

Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors

DEVICE

Chemotherapy: GP/GEMOX

Chemotherapy: GP/GEMOX

DRUG

FGFR Inhibitor

FGFR Inhibitor

DRUG

IDH1 mutation inhibitor

IDH1 mutation inhibitor

DRUG

KRAS mutation inhibitor

KRAS mutation inhibitor

DRUG

NTRK mutation inhibitor

NTRK mutation inhibitor

DRUG

BRAF V600E mutation inhibitor

BRAF V600E mutation inhibitor

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-10
Primary Completion
2028-08-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07729917 on ClinicalTrials.gov